Advertisement

Microalbuminuria in Perspectives

  • Carl Erik Mogensen

Abstract

The development of immuno-assays (including radio-immuno-assays) in the beginning of the 1960s allowed measurement of previously undetectable amounts of albumin in the urine [1], [2]. Initially procedures were complicated, slow, and in general expensive. However, there has been a rapid development in this area, so by now easy, quick and clinically readily applicable procedures are available for routine use in daily diabetes care as well as elsewhere [2]–[7].

Keywords

Diabetic Nephropathy Albumin Excretion Rate Diabetic Kidney Disease United Kingdom Prospective Diabetes Study Heart Outcome Prevention Evaluation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Mogensen CE. Microalbuminuria, blood pressure and diabetic renal disease: origin and development of ideas. In: Mogensen CE (ed), The Kidney and Hypertension in Diabetes Mellitus. Kluwer Academic Publ, 2000, pp 655–706.Google Scholar
  2. 2.
    Thomas SM, Viberti GC. Is it possible to predict diabetic kidney disease (review). J Endo Inv 2000;23:44–53.Google Scholar
  3. 3.
    Baenziger JC. Reporting units for albumin/creatinine ratio. Laboratory Med 2000;31:597.Google Scholar
  4. 4.
    Marshall SM. Blood pressure control, microalbuminuria and cardiovascular risk in type 2 diabetes mellitus. Diabetic Med 1999;16:358–372.PubMedCrossRefGoogle Scholar
  5. 5.
    Mogensen CE, Vestbo E, Poulsen PL, Christiansen C, Damsgaard EM, Eiskjaer H, Fr0land A, Hansen KW, Nielsen S, Pedersen MM. Microalbuminuria and potential confounders. Diabetes Care 1995;18:572–581.PubMedGoogle Scholar
  6. 6.
    Mogensen CE. Prediction of clinical diabetic nephropathy in IDDM patients. Alternatives to microalbuminuria? Diabetes 1990;37:761–767.CrossRefGoogle Scholar
  7. 7.
    Thomas SM. What should we do about microalbuminuria? In: Gill GV, Pickup JC, Williams G (eds), Difficult Diabetes. Blackwell Science Ltd, Oxford, 2001.Google Scholar
  8. 8.
    Dinneen S, Gerstein HC. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature. Arch Intern Med 1997;157:1413–1418.PubMedCrossRefGoogle Scholar
  9. 9.
    Schmitz A, Vaeth M. Microalbuminuria: a major risk factor in non-insulin-dependent diabetes: a 10-year follow-up study of 503 patients. Diabetic Med 1988;5:126–134.PubMedCrossRefGoogle Scholar
  10. 10.
    Chaturvedi N. Should all type 1 diabetic microalbuminuric patients receive ACE inhibitors? A mega regression analysis. Ann Intern Med 2001, in press.Google Scholar
  11. 11.
    Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253–259.CrossRefGoogle Scholar
  12. 12.
    The Heart Outcomes Prevention Evaluation Study Investigators. Effects of angiotensin-converting-enzyme inhibitor, ramipril, on death from cardiovascular causes, myorcardial infarction and stroke in high-risk patients. N Engl J Med 2000;342:145–153.CrossRefGoogle Scholar
  13. 13.
    Gerstein HC. Cardiovascular and metabolic benefits of ACE inhibition. Diabetes Care 2000;23:882.PubMedCrossRefGoogle Scholar
  14. 14.
    The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 2000;342:381–389.CrossRefGoogle Scholar
  15. 15.
    Warram JH, Scott LJ, Hanna LS, Wantman M, Cohen SE, Laffel LMB, Ryan L, Krolewski AS. Progression of microalbuminuria to proteinuria in type 1 diabetes. Nonlinear relationship with hyperglycemia. Diabetes 2000;49:94–100.PubMedCrossRefGoogle Scholar
  16. 16.
    Williams B. The unique vulnerability of diabetic subjects to hypertensive injury. Journal of Human Hypertension 1999;13(S2):S3–S8.PubMedCrossRefGoogle Scholar
  17. 17.
    Mogensen CE, Damsgaard EM, Froland A, Hansen KW, Nielsen S, Pedersen MM, Schmitz A, Thuesen L, Osterby R. Reduced glomerular filtration rate and cardiovasc ular damage in diabetes: a key role for abnormal albuminuria. Acta Diabetol 1992;29:201–213.CrossRefGoogle Scholar
  18. 18.
    Mogensen CE, Hansen KW, Osterby R, Damsgaard EM. Blood pressure elevation versus abnormal albuminuria in the genesis and prediction of renal disease in diabetes. Diabetes Care 1992;15:1192–1204.PubMedCrossRefGoogle Scholar
  19. 19.
    Cordonnier DJ, Pinel N, Barro C, et al. For the DIABIOPSIES GROUP. Expansion of the cortical interstitium is limited by converting enzyme inhibition in type 2 diabetic patients with glomerulosscle-rosis. J Am Soc Nephrol 1999;10:1253–1263.PubMedGoogle Scholar
  20. 20.
    Nankervis A, Nicholls K, Kilmartin G, Allen P, Ratnaike S, Martin FIR. Effects of Perindopril on renal histomorphometry in diabetic subjects with microalbuminuria: a 3-year placebo-controlled biopsy study. Metabolism 1998;47(suppl 1):12–15.PubMedCrossRefGoogle Scholar
  21. 21.
    Rudberg S, Østerby R, Bangstad H-J, Dahlquiest G, Persson B. Effect of angiotensin-converting enzyme inhibitor or beta-blocker on glomerular structural changes in young microalbuminuric patients with type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1999;42:589–595.PubMedCrossRefGoogle Scholar
  22. 22.
    Østerby R, Bangstad H-J, Rudberg S. Follow-up study of glomerular dimensions and cortical interstitium in microalbuminuric type 1 diabetic patients with or without antihypertensive treatment. Nephrol Dial Transplant 2000;15:1609–1616.PubMedCrossRefGoogle Scholar
  23. 23.
    Mathiesen ER, Hommel E, Hansen HP, Smidt UM, Parving H-H. Randomised controlled trial of long-term efficacy of Captopril on preservation of kidney function in normotensive patients with insulin-dependent diabetes and microalbuminuria. BMJ 1999;319:24–25.PubMedCrossRefGoogle Scholar
  24. 24.
    Caramori ML, Fioretto P, Mauer M. The need for early predictors of diabetic nephropathy risk. Is albumin excretion rate sufficient? Diabetes 2000;49:1399–1408.PubMedCrossRefGoogle Scholar
  25. 25.
    Mogensen CE. ACE-inhibition and antihypertensive treatment in diabetes: focus on microalbuminuria and macrovascular disease. JRAAS 2000;1:234–239.PubMedGoogle Scholar
  26. 26.
    Bradford HA. The environment and disease: association or causation? Proc R Soc Med 1965;58:295–300.Google Scholar
  27. 27.
    Bain SC, Chowdhur TA. Genetics of diabetic nephropathy and microalbuminuria (review). J Roy S Med 2000;93:62–66.Google Scholar
  28. 28.
    Schichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000;23(s2):B21–B30.Google Scholar
  29. 29.
    Adler AI, Stratton IM, Neil HAW, Yudkin JS, Matthews DR, Cull CA, Wright AD, Turner RC, Holman RR on behalf of the UK Prospective Diabetes Study Group. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): a prospective observational study. BMJ 2000;321:412–419.PubMedCrossRefGoogle Scholar
  30. 30.
    Lemley KV, Abdullah I, Myers BD, Meyer TW, Blouch K, Smith WE, Bennett PH, Nelson RG. Evolution of incipient nephropathy in type 2 diabetes mellitus. Kidney Int 2000;58:1228–1237.PubMedCrossRefGoogle Scholar
  31. 31.
    Nielsen S, Hove KY, Dollerup J, Poulsen PL, Christiansen JS, Schmitz O, Mogensen CE. Losartan modifies glomerular hyperfiltration and insulin sensitivity in type 1 diabetes. Diabetes, Obesity & Metabolism 2001, in press.Google Scholar
  32. 32.
    Mogensen CE. Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW, Cooper ME for the CALM Study Group. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000;321:1440–1444.PubMedCrossRefGoogle Scholar
  33. 33.
    Raats CJ, Vandenbo J, Berden JHM. Glomerular heparan-sulfate alterations-mechanisms and relevance for proteinuria (review) Kidney Int 2000;57:385–400.PubMedCrossRefGoogle Scholar
  34. 34.
    Bojestig M, Karlberg BE, Lindström T, Nystrom FH. Reduction of ACE activity is insufficient to lower micro-albuminuria in normotensive patients with type 1 diabetes. Diabetes Care 2001, in press.Google Scholar
  35. 35.
    Forsblom CM, Groop P-H, Ekstrand A, et al. Predictors of progression from normoalbuminuria to microalbuminuria in NIDDM. Diabetes Care 1998;21:1932–1938.PubMedCrossRefGoogle Scholar
  36. 36.
    Nielsen S, Schmitz A, Poulsen PL, Hansen KW, Mogensen CE. Albuminuria and 24-h ambulatory blood pressure in normoalbuminuric and microalbuminuric NIDDM patients: a longitudinal study. Diabetes Care 1995;18:1434–1441.PubMedCrossRefGoogle Scholar
  37. 37.
    Damsgaard EM, Frøland A, Jørgensen OD, Mogensen CE. Microalbuminuria as predictor of increased mortality in elderly people. BMJ 1990;300:297–300.PubMedCrossRefGoogle Scholar
  38. 38.
    Poulsen PL, Hansen KW, Mogensen CE. Ambulatory blood pressure in the transition from normo-to microalbuminuria. A longitudinal study in IDDM patients. Diabetes 1994;43:1248–1253.PubMedCrossRefGoogle Scholar
  39. 39.
    Rachmani R, Levi Z, Lidar M, et al. Considerations about the threshold value of microalbuminuria in patients with diabetes mellitus. Lessons from an 8-year follow-up study of 599 patients. Diabetes Res Clin Prac 2000;49:187–194.CrossRefGoogle Scholar
  40. 40.
    Royal College of Physicians of Edinburgh Diabetes Register Group. Near-normal urinary albumin concentrations predict progression to diabetic nephropathy in type 1 diabetes mellitus. Diabetic Med 2000;17:782–791.CrossRefGoogle Scholar
  41. 41.
    Schultz CJ, Neil HAW, Dalton RN et al. Risk of nephropathy can be detected before the onset of microalbuminuria during the early years after diagnosis of type 1 diabetes. Diabetes Care 2000;23:1811–1815.PubMedCrossRefGoogle Scholar
  42. 42.
    Schultz CJ, Dalton RN, Neil HAW, Konopelska-Bahu T, Dunger DB on behalf of the Oxford Regional Prospective Study Group. Markers of renal tubular dysfunction measured annually do not predict risk of microalbuminuria in the first few years after diagnosis of type 1 diabetes. Diabetologia 2001;44:224–229.PubMedCrossRefGoogle Scholar
  43. 43.
    Ravid M, Brosh D, Levi Z, Bar-Dayan V, Ravid D, Rachmani R. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. Ann Intern Med 1998;128:982–988.PubMedGoogle Scholar
  44. 44.
    Ravid M, Brosh D, Ravid-Safran D, Levy Z, Rachmani R. Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure and hyperglycemia. Arch Intern Med 1998;158:998–1004.PubMedCrossRefGoogle Scholar
  45. 45.
    Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993;118:577–581.PubMedGoogle Scholar
  46. 46.
    Kvetny J, Gregersen G, Pedersen RS. Randomised placebo-controlled trial of Perindopril in normotensive, normoalbuminuric patients with type 1 diabetes mellitus. QJM 2001; In press.Google Scholar
  47. 47.
    Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 1984;310:356–360.PubMedCrossRefGoogle Scholar
  48. 48.
    Valamadrid CT, Klein R, Moss SE, Klein BEK. The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus. Arch Intern Med 2000;160:1093–1100.CrossRefGoogle Scholar
  49. 49.
    Fioretto P, Vestra MD, Sailer A, Mauer M. Renal Structure in type 2 diabetic patients with micro-albumuria. In CE Mogensen (Ed.) The Kidney and Hypertension in Diabetes Mellitus. Kluwer Academic Publishers, 2000, pp 225–236.Google Scholar
  50. 50.
    Holman R, Turner R, Stratton I, et al. for United Kingdom Prospective Diabetes Study Group. Efficacy of atenolol and Captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: United Kingdom prospective diabetes study 39. BMJ 1998;317:713–720.CrossRefGoogle Scholar
  51. 51.
    Stratton IM, Adler AI, Neil HAW, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR on behalf of the UK Prospective Diabetes Study Group. Association of glycaemia with macro-vascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405–412.PubMedCrossRefGoogle Scholar
  52. 52.
    Stratton IM, Kohner EM, Aldington SJ, Turner RC, Holman RR, Manley SE, Matthews DR for the UKPDS Group. UKPDS 50: Risk factors for incidence and progression of retinopathy in type 2 diabetes over 6 years from diagnosis. Diabetologia 2001;44:156–163.PubMedCrossRefGoogle Scholar
  53. 53.
    Turner R, Holman R, Stratton 1 et al. for United Kingdom Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: United Kingdom prospective diabetes study 38. BMJ 1998;317:703–713.CrossRefGoogle Scholar
  54. 54.
    UKPDS 33. An intensive blood glucose control policy with sulphonylureas or insulin reduces the risk of diabetic complications in patients with Type 2 diabetes. Lancet 1998;352:837–853.CrossRefGoogle Scholar
  55. 55.
    American Diabetes Association. Diabetes Nephropathy. Diabetes Care 2001;24(suppl):S69–S72.Google Scholar
  56. 56.
    Deinum J, Rønn B, Mathiesen E, Derkx FHM, Hop WCJ, Schalekamp MADH. Increase in serum prorenin precedes onset of microalbuminuria in patients with insulin-dependent diabetes mellitus. Diabetologia 1999;42:1006–1010.PubMedCrossRefGoogle Scholar
  57. 57.
    Bojestig M, Nystrom FH, Arnqvist HJ, Ludvigsson J, Karlberg BE. The renin-angiotensin-aldosterone system is suppressed in adults with type 1 diabetes. JRAAS 2000;1:353–356.PubMedGoogle Scholar
  58. 58.
    Hansen KW, Pedersen MM, Christensen CK, Schmitz A, Christiansen JS, Mogensen CE. Normoalbuminuria ensures no reduction of renal function in type 1 (insulin-dependent) diabetic patients. Journal of Internal Med 1992;232:161–167.CrossRefGoogle Scholar
  59. 59.
    Sackmann H, Tran-Van T, Tack I, Hanaire-Broutin H, Tauber J-P, Ader J-L. Contrasting renal functional reserve in very long-term type 1 diabetic patients with and without nephropathy. Diabetologia 2000;43:227–230.PubMedCrossRefGoogle Scholar
  60. 60.
    Christensen CK, Mogensen CE. Effect of antihypertensive treatment on progression of disease in incipient diabetic nephropathy. Hypertension 1985;7:II109–II113.PubMedCrossRefGoogle Scholar
  61. 61.
    Pedersen MM, Christensen CK, Hansen KW, Christiansen JS, Mogensen CE. ACE-Inhibition and renoprotection in early diabetic nephropathy. Response to enalapril acutely and in long-lerm combination with conventional antihypertensive treatment. Clin Invest Med 1991;14:642–651.PubMedGoogle Scholar
  62. 62.
    Pedersen MM, Hansen KW, Schmitz A, Sorensen K, Christensen CK, Mogensen CE. Effects of ACE inhibition supplementary to beta blockers and diuretics in early diabetic nephropathy. Kidney Int 1992;41:883–890.PubMedCrossRefGoogle Scholar
  63. 63.
    Poulsen PL, Ebbehøj E, Nosadini R, et al. Early ACE-I intervention in microalbuminuric patients with type 1 diabetes: effects on albumin excretion, 24:h ambulatory blood pressure and renal function. Diabetes Metab 2001, in press.Google Scholar
  64. 64.
    Cooper ME, McNally P, Boner C. Antihypertensive treatment in NIDDM with special reference to abnormal albuminuria. In: Mogensen CE (ed), The Kidney and Hypertension in Diabetes Mellitus, 5th ed. Kluwer Academic Publishers, Boston, MA, 2000.Google Scholar
  65. 65.
    Poulsen PL, Ebbehoj E, Mogensen CE. Lisinopril reduces albuminuria during exercise in low grade microalbuminuric type 1 diabetic patients: a double blind randomised study. J Intern Med 2001, in press.Google Scholar
  66. 66.
    Laffel LMB, McCill JB, Cans DJ, on behalf of the North American Microalbuminuria Study Group. The beneficial effect of angiotensin-converting enzyme inhibition wilh Captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. Am J Med 1995;99:497–504.PubMedCrossRefGoogle Scholar
  67. 67.
    Crepaldi C, Carta Q, Deferrari G, et al. Effects of lisinopril and niredipine on the progression to overt albuminuria in IDDM patients with incipient nephropathy and normal blood pressure. The Italian Microalbuminuria Study Group in IDDM. Diabetes Care 1998;21:104–110.PubMedCrossRefGoogle Scholar
  68. 68.
    The ATLANTIS study group. Low-dose ramipril reduces microalbuminuria in type 1 diabetic patients without hypertension: results of a randomized controlled trial. Diabetes Care 2000;23:1823–1829.CrossRefGoogle Scholar
  69. 69.
    Jerums C on behalf of the Melbourne Diabetic Nephropathy Study Group, Melbourne, Australia. ACE inhibition vs calcium channel blockade in normotensive type 1 and type 2 diabetic patients with microalbuminuria. Nephrol Dial Transplant 1998;13:1065–1066.Google Scholar
  70. 70.
    The EUCLID study group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normalbuminuria or microalbuminuria. Lancet 1997;349:1787–1792.CrossRefGoogle Scholar
  71. 71.
    The European Study for the Prevention of Renal disease in Type 1 diabetes (ESPRIT). Three years of antihypertensive therapy has no detectable effect on renal structure in type 1 diabetic patients with albuminuria. Diabetes, 2001. In press.Google Scholar
  72. 72.
    Thomas W. Shen Y, Molitch ME, Steffes MW. Rise in albuminuria and blood pressure in patients who progressed to diabetic nephropathy in the diabetes control and complications trial. J Am Soc Nephrol 2001;12(2):333–340.PubMedGoogle Scholar
  73. 73.
    Borch-Johnsen K, Wenzel H, Viberti GC, Mogensen CE. Is screening and intervention for microalbuminuria worthwhile in patients with insulin dependent diabetes. BMJ 1993;306:1722–1725.PubMedCrossRefGoogle Scholar
  74. 74.
    The ACE-Inhibitors in Diabetic Nephropathy Trialist Group. Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data. Ann Intern Med 2001;134:370–379.Google Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2002

Authors and Affiliations

  • Carl Erik Mogensen
    • 1
  1. 1.Aarhus KommunehospitalAarhus CDenmark

Personalised recommendations